A vasculitis diagnosis changed my life, but it doesn’t define me
Rachel Young learns to walk again in 2022. (Photos courtesy of Rachel Young) This is Rachel Young’s story: Young hikes in 2023. If I had ever heard the term “vasculitis” before my…
Throughout May, ANCA Vasculitis News is recognizing Vasculitis Awareness Month with a variety of stories that represent different perspectives on life with vasculitis that we hope help to inspire and empower our readers. These stories highlight some of the unique challenges of living with vasculitis, as well as stories of hope, inspiration, and other topics that help to generate awareness among the ANCA vasculitis community. Follow along with the series here or visit us on Facebook or Instagram using the hashtag #ANCASpotlight.
May 31, 2024
by
Bionews Staff
GPA vasculitis wreaked havoc in my life, but I’m enduring
Christine MacFadyen’s symptoms appeared 15 years ago, and she was diagnosed five years ago. (Photos courtesy of Christine MacFadyen) This is Christine MacFadyen’s story: I was a fun-loving, always smiling, energetic, adventurous woman.
Read moreVasculitis Awareness Month aims to put focus on community voices
May will be an activity-filled month for people living with vasculitis — and for doctors, researchers, and advocates in the field — as the world recognizes Vasculitis Awareness Month (VAM), and International Vasculitis Day…
Recent Posts
- Plasma exchange improves early kidney recovery in AAV: Study January 29, 2025
- IVIg therapy reduces relapses, eases disability in EGPA patients: Study January 27, 2025
- Doctors not often overly rosy in views of overall health with AAV January 22, 2025
- ANCA-associated vasculitis with kidney damage trial tests lixudebart January 15, 2025
- AAV enrollment into CAR T-cell trial pushed to 2nd half of 2025 January 13, 2025
- Kidney function at diagnosis linked to outcomes in pediatric AAV January 8, 2025
- Risk of infection high with AAV, and it can be severe January 6, 2025
- Lower glucocorticoid dosing regimen may be risky, study finds December 18, 2024
- Q32 Bio pushes back Phase 2 trial of ADX-097 in AAV patients December 16, 2024
- Enrollment open for trial testing NKX019 cell therapy in AAV December 11, 2024